Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on ArriVent BioPharma, Inc., retaining the price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robert Burns has given his Buy rating due to a combination of factors including promising clinical trial results and strategic development plans by ArriVent BioPharma, Inc. The company is expecting top-line results from its pivotal Phase 3 FURVENT trial in early 2026, which is evaluating firmonertinib against platinum-based chemotherapy in patients with a specific type of lung cancer. Previous trials have shown firmonertinib to have favorable outcomes compared to competitors, with impressive response rates and a manageable safety profile.
Additionally, ArriVent is preparing to start enrollment for the pivotal ALPACCA trial, following encouraging data from earlier studies. This trial aims to support potential accelerated and full approval for firmonertinib in treating non-small cell lung cancer with specific mutations. Burns’s valuation of ArriVent uses a discounted cash flow approach, considering a 65% probability of launch for firmonertinib in targeted cancer types, leading to a price target of $40 per share. However, he notes potential risks such as slower trial enrollment and negative efficacy data.
Burns covers the Healthcare sector, focusing on stocks such as BioNTech SE, Exelixis, and Zymeworks. According to TipRanks, Burns has an average return of -11.5% and a 35.67% success rate on recommended stocks.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $38.00 price target.